Precision Medicine for Sng/Pain Control

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Nov 29, 2021

Keywords

ClinConnect Summary

This clinical trial, called "Precision Medicine for Sng/Pain Control," is studying how different treatments can help people with chronic shoulder pain and myofascial pain syndrome. Researchers believe that people respond differently to treatments like low-level laser therapy, ultrasound, and prolotherapy based on their genetic makeup. The trial aims to identify specific genetic markers that may predict how well these treatments work for each person. By doing this, they hope to create personalized treatment plans that are more effective in managing pain.

To participate in the trial, individuals should be between 20 and 100 years old and have a diagnosis of myofascial pain syndrome. Those who have active infections, cancer, or certain blood disorders, or who have received specific injections in the past three months, cannot join. Participants will receive one or more of the treatments and will have their progress monitored. Blood and urine samples will also be collected to look for potential markers that can help guide future pain management approaches. The researchers are excited about the possibility of using these findings to improve pain relief for many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Age between 20-100 years old.
• • (2) Diagnosed as myofascial pain syndrome patients and willing to receive treatment (including LLLT, therapeutic ultrasound, and local dextrose injection therapy).
• Exclusion Criteria:
• • Those having active infection, malignancy, and hematological diseases were excluded. The patients had received local injection at upper trapezius within 3 months are also excluded.